Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.

ABSTRACT:

Background

Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective data are limited.

Objective

To investigate whether SAbR is effective in the management of primary RCCs.

Design, setting, and participants

Patients with biopsy-confirmed radiographically enlarging primary RCC (≤5 cm) were enrolled. SAbR was delivered in either three (12 Gy) or five (8 Gy) fractions.

Outcome measurements and statistical analysis

The primary endpoint was local control (LC) defined as a reduction in tumor growth rate (compared with a benchmark of 4 mm/yr on active surveillance) and pathologic evidence of

SUBMITTER: Hannan R 

PROVIDER: S-EPMC10440291 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature